Drugs / Capectitabine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06932068 Background | Mar 2025 → Oct 2026 expected | Her2-receptor negative breast cancer, gastroesophageal adenocarcinoma | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capectitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06932068 ↗ |
| Route | Oral | “1000 mg/m2, po” NCT06932068 ↗ |